美国境内制药公司2025年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ DRUGS MADE IN AMERICA ACQUISITION CORP. TABLE OF CONTENTS DRUGS MADE IN AMERICA ACQUISITION CORP.STATEMENT OF OPERATIONS NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Drugs Made In America Acquisition Corp. (the “Company”) is a blank check company newly incorporated in the Cayman Islands onMay23, 2024. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share Although the Company may acquire a business in any industry, it intends to focus on companies in the pharmaceutical industry. TheCompany is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early As of March 31, 2025, the Company had not commenced any operations. All activity for the period fromMay23, 2024 (inception)through March 31, 2025relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is describedbelow, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not The registration statement for the Company’s Initial Public Offering was declared effective on January 7, 2025 and the post-effectiveamendment to the registration statement was declared effective on January 27, 2025. On January 29, 2025, the Company consummatedthe Initial Public Offering of20,000,000units (the “Units” and, with respect to the ordinary shares included in the Units being offered,the “Public Shares”) at $10.00per Unit, generating proceeds of $200,000,000, which is described in Note 3. On February 18, 2025, the Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of400,000units (the “PrivatePlacement Units”) at a price of $10.00per Private Placement Unit in a private placement to Drugs Made In America Acquisition LLC(the “Sponsor”), for $4,000,000, of which $1,100,000was not received and included as share subscription receivable. Since the InitialPublic Offering until March 31, 2025, the Sponsor has paid $247,621in expenses on behalf of the Company reducing the sharesubscription receivable on the unaudited balance sheet to $852,379. Simultaneously with the sale of the over-allotment option Units on The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial PublicOffering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generallytoward consummating a Business Combination. There is no assurance that the Company will be able to complete a BusinessCombination successfully. The Company must complete one or more initial Business Combinations with one or more operatingbusinesses or assets with a fair market value equal to at least80% of the net assets held in the Trust Account (as defined below) Following the closing of the Initial Public Offering on January 29, 2025 and the over-allotment option closing on February 18, 2025 anamount of $231,150,000($10.05per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale ofthe Private Placement Units was placed in a trust account (“Trust Account”), located in the UnitedStates and invested only inU.S.government treasury obligations with a maturity of 185days or less or in money market funds meeting certain conditions underRule2a-7 under the Investment Company Act which invest only in direct U.S.government treasury obligations and/or held as cash orcash items (including in demand deposit accounts), as determined by the Company, until the earlier of: (i)the completion of a BusinessCombination; (ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Transaction costs amounted to $8,898,201consisting of $1,150,000of cash underwriting fees, $6,900,000of deferred underwriting The Company will provide the holders of the outstanding Public